COVA4231, a potent CD3/CD33 bispecific FynomAb with IgG-like pharmacokinetics for the treatment of acute myeloid leukemia.
Klupsch K, Baeriswyl V, Scholz R, Dannenberg J, Santimaria R, Senn D, Kage E, Zumsteg A, Attinger-Toller I, von der Bey U, König-Friedrich S, Dupuy F, Lembke W, Albani C, Wendelspiess S, Dinkel L, Saro D, Hepler RW, Laszlo GS, Gudgeon CJ, Bertschinger J, Brack S, Walter RB.
Klupsch K, et al. Among authors: zumsteg a.
Leukemia. 2019 Mar;33(3):805-808. doi: 10.1038/s41375-018-0249-z. Epub 2018 Sep 11.
Leukemia. 2019.
PMID: 30206306
No abstract available.